exemestane + goserelin + palbociclib

This is a combination regimen consisting of three drugs—exemestane, goserelin, and palbociclib—used primarily in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic or advanced breast cancer in premenopausal women. - **Exemestane** is an aromatase inhibitor that blocks estrogen synthesis, reducing estrogen levels and thus limiting the growth stimulus for HR+ breast cancer cells. - **Goserelin** is a gonadotropin-releasing hormone (GnRH) agonist that suppresses ovarian function, leading to decreased production of estrogen from the ovaries—a necessary step for effective use of aromatase inhibitors in premenopausal women. - **Palbociclib** is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that blocks cell cycle progression from G1 to S phase, thereby inhibiting proliferation of cancer cells. The combination has demonstrated improved progression-free survival compared to chemotherapy with capecitabine or endocrine therapy alone in clinical trials involving premenopausal patients with HR+/HER2- metastatic breast cancer[6][7]. The regimen requires careful monitoring due to risks such as neutropenia and other hematologic toxicities.